Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Librede : Inc. Receives Patent for Cannabidiolic Acid (CBDA) Production in Yeast

07/24/2018 | 05:01am EDT

Librede, a leader in natural cannabinoid biosynthesis, has been granted a new patent for the production of cannabidiolic acid (CBDA) in microorganisms. The patent, Production of Cannabidiolic Acid in Yeast, describes the modification of yeast to produce CBDA from simple feedstocks such as sugar. CBDA is a naturally occurring cannabinoid found in hemp and cannabis which is used to produce cannabidiol (CBD). Cannabidiol has been shown to have a wide range of therapeutic properties, including treatment of epilepsy, for which a CBD-based therapeutic has won recent FDA approval. Librede’s fermentation-based cannabinoid production platform has demonstrated that natural CBD can be produced outside of the cannabis plant using yeast, in a process that is similar to making beer. Librede is now in the process of continuing technology development through optimization and scaling for industrial production in large fermenters. Dr. Anthony Farina, Librede’s Chief Scientific Officer, explains: “We have been building our platform around the natural biochemistry in the cannabis plant that gives rise to a diverse set of compounds, with our focus being on therapeutic applications. Having engineered cannabidiol synthesis in the laboratory, we are now beginning the process of scaled up production.”

Fermentation for the production of high value, complex, natural products offers a preferred route to synthesis at an industrial scale. Librede’s biosynthetic approach has several potential advantages over agricultural-based methods including protection from supply volatility, improved consistency, reduced cost, and lower environmental impact. Dr. Jason Poulos, CEO of Librede, explains: “The use of fermentation to produce these compounds represents the future of industrial scale cannabinoid production. As more cannabinoids are shown to have therapeutic value, we must find a way to produce these compounds in a sustainable way. Utilizing the synthetic power of biology allows us economical access to these compounds while minimizing environmental impacts. The future of all cannabinoid production may not be large farm fields but instead compact and highly efficient fermenters.”

About Librede:

Librede is a synthetic biology company that uses biologically-based approaches to produce high value natural products with a focus on cannabinoids. Librede’s patented yeast-based cannabinoid production platform can provide therapeutic cannabinoids to diverse markets in an economically and environmentally sustainable way.


© Business Wire 2018
Latest news "Companies"
06:33aNorway police reinforcing oil and gas security after Nord Stream blasts
RE
06:33aMrc Global Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
06:33aThor Industries Inc : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
06:32aCopper drops to two-month low on buoyant dollar, recession fears
RE
06:32aHeadwater Gold Commences Multi-Rig Drill Program at the Spring Peak Project, Nevada to Follow up Epithermal Vein Discoveries
AQ
06:31aSoltech Energy's rights issue oversubscribed. The company will thus receive SEK 270 million before issue costs
AQ
06:31aWallbridge Adds New, Near-Surface Gold Zones in Tabasco and Area 51, Hits Higher-Grade Intercepts in Nearby Ripley Zone
AQ
06:31aAnne McEntee Joins MRC Global's Board of Directors
AQ
06:31aNextEra Energy and NextEra Energy Partners to present at the 2022 Wolfe Research Utilities, Midstream & Clean Energy Conference
PR
06:31aSilicon Labs Expands in India With New Office in Hyderabad
PR
Latest news "Companies"